FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113669930> ?p ?o ?g. }

• W2113669930 endingPage "e1000321" @default.
• W2113669930 startingPage "e1000321" @default.
• W2113669930 abstract "Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients.Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median -0.2 and -0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus -44 cells/mm(3), p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood.In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection.ClinicalTrials.gov NCT00515827" @default.
• W2113669930 created "2016-06-24" @default.
• W2113669930 creator A5008716404 @default.
• W2113669930 creator A5021144115 @default.
• W2113669930 creator A5024560316 @default.
• W2113669930 creator A5029030800 @default.
• W2113669930 creator A5029362932 @default.
• W2113669930 creator A5038307269 @default.
• W2113669930 creator A5041229585 @default.
• W2113669930 creator A5045529124 @default.
• W2113669930 creator A5048198586 @default.
• W2113669930 creator A5048457292 @default.
• W2113669930 creator A5060335470 @default.
• W2113669930 creator A5065227576 @default.
• W2113669930 creator A5071400358 @default.
• W2113669930 creator A5072899489 @default.
• W2113669930 creator A5082310426 @default.
• W2113669930 creator A5085282020 @default.
• W2113669930 creator A5090310672 @default.
• W2113669930 date "2010-08-10" @default.
• W2113669930 modified "2023-10-17" @default.
• W2113669930 title "The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial" @default.
• W2113669930 cites W1984252140 @default.
• W2113669930 cites W1984902481 @default.
• W2113669930 cites W1991502041 @default.
• W2113669930 cites W2005141763 @default.
• W2113669930 cites W2007607803 @default.
• W2113669930 cites W2019323140 @default.
• W2113669930 cites W2056833651 @default.
• W2113669930 cites W2068400385 @default.
• W2113669930 cites W2117211286 @default.
• W2113669930 cites W2117962018 @default.
• W2113669930 cites W2119974226 @default.
• W2113669930 cites W2139552123 @default.
• W2113669930 cites W2140573695 @default.
• W2113669930 cites W2150504993 @default.
• W2113669930 cites W2159657457 @default.
• W2113669930 cites W2160919872 @default.
• W2113669930 cites W2161993838 @default.
• W2113669930 cites W2164273972 @default.
• W2113669930 doi "https://doi.org/10.1371/journal.pmed.1000321" @default.
• W2113669930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3934995" @default.
• W2113669930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20711481" @default.
• W2113669930 hasPublicationYear "2010" @default.
• W2113669930 type Work @default.
• W2113669930 sameAs 2113669930 @default.
• W2113669930 citedByCount "255" @default.
• W2113669930 countsByYear W21136699302012 @default.
• W2113669930 countsByYear W21136699302013 @default.
• W2113669930 countsByYear W21136699302014 @default.
• W2113669930 countsByYear W21136699302015 @default.
• W2113669930 countsByYear W21136699302016 @default.
• W2113669930 countsByYear W21136699302017 @default.
• W2113669930 countsByYear W21136699302018 @default.
• W2113669930 countsByYear W21136699302019 @default.
• W2113669930 countsByYear W21136699302020 @default.
• W2113669930 countsByYear W21136699302021 @default.
• W2113669930 countsByYear W21136699302022 @default.
• W2113669930 countsByYear W21136699302023 @default.
• W2113669930 crossrefType "journal-article" @default.
• W2113669930 hasAuthorship W2113669930A5008716404 @default.
• W2113669930 hasAuthorship W2113669930A5021144115 @default.
• W2113669930 hasAuthorship W2113669930A5024560316 @default.
• W2113669930 hasAuthorship W2113669930A5029030800 @default.
• W2113669930 hasAuthorship W2113669930A5029362932 @default.
• W2113669930 hasAuthorship W2113669930A5038307269 @default.
• W2113669930 hasAuthorship W2113669930A5041229585 @default.
• W2113669930 hasAuthorship W2113669930A5045529124 @default.
• W2113669930 hasAuthorship W2113669930A5048198586 @default.
• W2113669930 hasAuthorship W2113669930A5048457292 @default.
• W2113669930 hasAuthorship W2113669930A5060335470 @default.
• W2113669930 hasAuthorship W2113669930A5065227576 @default.
• W2113669930 hasAuthorship W2113669930A5071400358 @default.
• W2113669930 hasAuthorship W2113669930A5072899489 @default.
• W2113669930 hasAuthorship W2113669930A5082310426 @default.
• W2113669930 hasAuthorship W2113669930A5085282020 @default.
• W2113669930 hasAuthorship W2113669930A5090310672 @default.
• W2113669930 hasBestOaLocation W21136699301 @default.
• W2113669930 hasConcept C126322002 @default.
• W2113669930 hasConcept C142462285 @default.
• W2113669930 hasConcept C142724271 @default.
• W2113669930 hasConcept C168563851 @default.
• W2113669930 hasConcept C203014093 @default.
• W2113669930 hasConcept C203092338 @default.
• W2113669930 hasConcept C204787440 @default.
• W2113669930 hasConcept C27081682 @default.
• W2113669930 hasConcept C2776185481 @default.
• W2113669930 hasConcept C2780404665 @default.
• W2113669930 hasConcept C2781413609 @default.
• W2113669930 hasConcept C2993143319 @default.
• W2113669930 hasConcept C3013748606 @default.
• W2113669930 hasConcept C71924100 @default.
• W2113669930 hasConcept C90924648 @default.
• W2113669930 hasConceptScore W2113669930C126322002 @default.
• W2113669930 hasConceptScore W2113669930C142462285 @default.
• W2113669930 hasConceptScore W2113669930C142724271 @default.
• W2113669930 hasConceptScore W2113669930C168563851 @default.
• W2113669930 hasConceptScore W2113669930C203014093 @default.

• next